CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Response Oncology Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Response Oncology Inc
1805 Moriah Woods Blvd
Phone: (901) 761-7000p:901 761-7000 MEMPHIS, TN  38117-7121  United States Ticker: ROIXROIX

Business Summary
Response Oncology, Inc. was, prior to the sales of its assets, a comprehensive cancer management company. As of May 20, 2002, the Company had liquidated substantially all of its operating assets and anticipates that the remaining assets will be liquidated and all wind-down activities completed by the end of 2002. Prior to the sale of its assets, the Company provided advanced cancer treatment services through outpatient facilities known as IMPACT Centers under the direction of practicing oncologists; owned the assets of and managed the non-medical aspects of oncology practices; compounded and dispensed pharmaceuticals to certain oncologists for a fixed or cost plus fee; and conducted outcomes research on behalf of pharmaceutical manufacturers.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/200212/31/2001-YesYes--

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer Charles E.Sweet 66 4/1/2002 4/1/2002
Chief Financial Officer, Executive Vice President Peter A.Stark 38 11/1/2000
Director Joames A.Skinner 68 4/1/2002 4/1/2002

General Information
Number of Employees: 10 (As of 5/20/2002)
Outstanding Shares: 12,178,701 (As of 6/17/2002)
Shareholders: 1,831
Stock Exchange: OTC
Federal Tax Id: 621212264
Fax Number: (901) 763-7045
Email Address: info@responseoncology.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, August 28, 2023